New branches lost thirty crores, a drag that will likely persist
A healthcare company rooted in the ancient human need for sight has crossed a symbolic threshold — two thousand crores in annual revenue — marking not just a financial milestone but a moment of reckoning between ambition and operational reality. Dr Agarwal's Health Care, expanding aggressively across India in FY26, demonstrated that growth in medicine is never purely a matter of capital: it demands real estate, trained hands, and institutional patience. The numbers told one story of success, while the staffing attrition and greenfield losses quietly told another, more complicated one.
- For the first time in its history, the company breached the 2,000 crore revenue barrier, with total income reaching 2,125 crores and EBITDA margins nudging upward to 28.9% — a genuine signal of institutional maturity.
- Yet beneath the headline figures, newly built facilities collectively bled 30 crores in losses, and one-time merger and relocation costs further compressed the profitability that investors had come to expect.
- Paramedical staff are leaving at rates between 21 and 25 percent annually, a quiet crisis that threatens the clinical consistency and training continuity on which a multi-site healthcare network depends.
- Management is pressing forward regardless, committing 380–400 crores to open 60 new facilities in FY27, a bold wager that scale will eventually absorb the friction costs of rapid expansion.
- The real bottleneck may not be financial at all — securing real estate and navigating compliance requirements have emerged as the true limiting factors, problems that money alone cannot accelerate.
Dr Agarwal's Health Care closed FY26 having crossed a threshold it had never reached before: two thousand crores in annual revenue. Total income came in at 2,125 crores, up nearly 21 percent year-on-year, while EBITDA grew even faster at 22.2 percent, nudging margins 31 basis points higher to 28.9 percent. The company also made a deliberate push into higher-margin surgical territory, with robotic cataract procedures surging 87 percent — a sign that specialty focus was beginning to reshape the revenue mix.
But the growth came with visible costs. Greenfield branches opened during the year — facilities built from scratch rather than acquired — collectively lost around 30 crores. Merger-related expenses and a corporate office relocation added further one-time pressure. The refractive surgery segment, unlike the buoyant cataract business, grew more slowly, hinting at competitive or demand-side headwinds in that corner of the market.
The staffing picture added another layer of concern. Paramedical employees were leaving at annual rates of 21 to 25 percent — a churn level that strains training pipelines and operational consistency across a growing clinic network. These are not problems that resolve themselves with scale.
Looking ahead, management has committed to opening 60 new facilities in FY27 — 40 surgical centers and 20 clinics — at a capital cost of 380 to 400 crores. Acquisition-related spending is also expected to continue, suggesting inorganic growth remains part of the playbook. The harder constraint, however, is proving to be real estate: finding and securing suitable locations, and clearing compliance hurdles, has become a genuine bottleneck that capital cannot simply accelerate.
For CEO Dr. Adil Agarwal and CFO Yashwant Venkal, the question analysts are quietly asking is whether the organization can sustain financial discipline while simultaneously solving the ground-level puzzles of staffing and real estate that will determine whether the 60-facility ambition becomes reality or remains a plan on paper.
Dr Agarwal's Health Care Ltd crossed a threshold in its fiscal year ending March 2026 that the company had never reached before: two thousand crores in annual revenue. The milestone arrived amid a broader push to remake the business—adding clinics and surgical centers across India, investing in robotic technology, and absorbing a merger—but the path forward revealed the friction points that come with rapid growth in healthcare.
The numbers on the surface looked strong. Total income for FY26 reached 2,125 crores, up 20.9 percent from the prior year. Earnings before interest, taxes, depreciation, and amortization grew even faster, climbing 22.2 percent year-on-year, and the company managed to expand its profit margins by 31 basis points to 28.9 percent. These are the kinds of figures that catch investor attention. The company had also begun to shift its surgical mix toward higher-margin procedures. Robotic cataract surgeries, a specialty requiring significant capital investment and technical expertise, surged 87 percent in the same period. High-end cataract work more broadly showed robust growth as well.
But beneath these headline gains lay a more complicated picture. The company opened new greenfield branches during the year—facilities built from scratch rather than acquired—and these startups lost approximately 30 crores collectively. That drag on profitability was compounded by one-time costs tied to a merger process and the relocation of the corporate office. The refractive surgery segment, which handles procedures like LASIK, grew more slowly than cataract work, suggesting that market demand or competitive dynamics in that corner of the business were not as favorable. And the company was bleeding paramedical staff at rates between 21 and 25 percent annually, a churn rate that threatens operational continuity and training consistency across a network of clinics.
The expansion agenda for the coming year was ambitious. Management planned to commission 60 new facilities in FY27—40 surgical centers and 20 clinics—requiring a capital expenditure of between 380 and 400 crores. This represented a significant bet on growth, but it also meant that the margin pressure from new branches would likely persist. The company had also spent about 85 crores in FY26 on acquisition-related payments and expected to spend between 60 and 65 crores in the year ahead, suggesting that inorganic growth remained part of the strategy.
The real constraint, however, appeared to be on the ground. Securing real estate for new facilities and navigating compliance requirements had become a bottleneck. These are not problems that capital alone solves. They require time, relationships, and regulatory patience. The company's ability to execute its 60-facility plan would depend partly on how quickly these obstacles could be cleared. Meanwhile, the loss of paramedical staff at such high rates raised questions about workplace conditions, compensation, or career progression in the roles that form the backbone of clinical operations.
Dr. Adil Agarwal, the CEO, and Yashwant Venkal, the CFO, fielded questions from analysts about the path ahead. The company had reached a significant scale milestone, but the next phase of growth would test whether the organization could manage expansion without sacrificing the margins and operational stability that had gotten it here. The robotic cataract business showed that specialty focus could drive growth, but the slower refractive surgery segment and the persistent drag from new branches suggested that not all parts of the business were moving at the same speed. For investors watching the stock, the question was whether management could solve the real estate and staffing puzzles while maintaining the financial discipline that had carried the company to two thousand crores.
Notable Quotes
We plan to add about 40 surgical facilities and 20 clinics, with total CapEx spend around 380 to 400 crores— Dr. Adil Agarwal, CEO
One-time expenses in Q4 were related to merger process, corporate office relocation, and increased marketing on Facebook— Yashwant Venkal, CFO
The Hearth Conversation Another angle on the story
The company hit two thousand crores in revenue for the first time. That's a real milestone. But I'm reading that new branches lost thirty crores. How does that square with the growth story?
It's the cost of building the future. When you open a greenfield facility—a brand new clinic or surgical center—it takes time to fill the beds, build the patient base, train the staff. You're spending money before you're making it. That's normal in healthcare expansion, but it does compress margins in the near term.
And the staff attrition—21 to 25 percent for paramedical workers. That seems high. What's driving that?
The source doesn't say explicitly, but in healthcare, paramedical staff are often underpaid relative to their training and the physical demands of the work. High turnover in those roles is a chronic problem across the sector. It affects continuity of care and training costs.
The company is planning 60 new facilities next year and spending 380 to 400 crores on capital. That's aggressive. Do they have the real estate locked down?
No. Management actually flagged real estate acquisition and compliance as challenges that could slow expansion. That's a candid admission. You can have the capital and the strategy, but if you can't find the buildings or navigate the regulatory maze, you're stuck.
What about the robotic cataract surgeries? Those grew 87 percent. Is that the future of the business?
It's certainly a bright spot. Robotic procedures command higher margins and attract patients willing to pay premium prices. But refractive surgery—LASIK and similar—grew slower. So the company is succeeding in some segments and struggling in others. That's a sign that execution and market positioning matter as much as capital.
One last thing: the merger expenses and office relocation hit Q4. Is that a one-time thing, or should investors expect more disruption?
Those were explicitly one-time. But mergers and rapid expansion always carry hidden costs—integration challenges, culture clashes, systems that don't talk to each other. The financial statements capture some of it. The rest shows up in staff turnover and operational friction.